Bioabsorbable Stents Market - Regional Synopsis
North America Market Insights
North America effectively dominates the bioabsorbable stents market with a projected 41.8% revenue share by the end of 2037, which includes a 15.7% growth rate. The region’s leadership originates from innovative healthcare infrastructure, favorable reimbursement policies, and a surge in PCI procedure volumes. Besides, Medicare covers 85% of inpatient bioabsorbable stent procedures in the U.S., and the single-payer system in Canada ensures broad accessibility. Meanwhile, the FDA’s rapid acceptance pathway, catering to 13 to 19 months, also accelerates the innovation, with over 4 next-generation stents anticipated to launch by the end of 2026, thereby suitable for uplifting the market.
The bioabsorbable stents market in the U.S. is significantly gaining traction and accounts for 92% of the region’s market share. The market’s growth in the country is fueled by Medicare’s USD 855 million yearly spending on these devices. Besides, the CDC has stated that an estimated 800,250 yearly PCI procedures take place with the utilization of these devices, based on which adoption rates have doubled since 2020. The shift towards outpatient settings, constituting 57% of procedures in 2025, and the FDA’s Breakthrough Device designation for more than 2 latest stent technologies as of 2024 are other key trends positively impacting the market in the country.
The bioabsorbable stents market in Canada is steadily growing with a 15% growth rate. The market’s upliftment is highly attributed to the existence of provincial health plans that cover 80% of stent expenses. In addition, Ontario has successfully funded approximately 200,250 procedures yearly, while Atlantic provinces cover up to 45%. Besides, the 2023 Canada-based Cardiovascular Society guidelines have readily prioritized bioabsorbable stents for young patients, which also drives the market demand by 28%. Therefore, all these factors are responsible for boosting the market growth in the country.
Europe Market Insights
Europe in the bioabsorbable stents market is projected to account for 30.5% of the revenue share by the end of the forecast period. The market’s upliftment in the region is effectively fueled by EU-based standardization of reimbursement policies, an increase in PCI volumes, and a surge in the aging population. Besides these factors, Germany is leading the market adoption with €4.3 billion in yearly spending, while the UK and France have readily prioritized affordability and mandated outcomes-specific pricing for stent procurement. The EU Medical Device Regulation (MDR) has escalated acceptances and reduced timelines by 32% since 2021, with over 10 next-generation stents greenlit as of 2023.
The bioabsorbable stents market in Germany is expected to capture 38% of the region’s revenue during the forecast timeline, owing to the existence of the €4.3 billion yearly market, along with 600,008 PCI procedures. Besides, the G-BA’s advanced fund provision has allocated €350 million per year for next-generation stents, and meanwhile, bundled payments cover almost 94% of procedures. Moreover, the outpatient adoption has increased with a growth rate of 21%, which is highly supported by AI-powered stent designs that are funded by Horizon Europe, thereby suitable for uplifting the market in the country.
The bioabsorbable stents market in the UK is gaining increased exposure by grabbing 22.5% of the region’s market share, of which £1.3 billion has been allocated for NHS spending as of 2023. NICE guidelines have prioritized bioabsorbable stents for patients under 65 years of age, which readily drives the yearly demand growth by 15.8%. Besides, the aspect of post-Brexit has resulted in the MHRA approving more than 8 latest stents in 2024, which has escalated the overall accessibility. Furthermore, the £220 million AI-based stent initiative effectively aims to diminish restenosis rates by almost 26% by 2030, thus creating an optimistic outlook for the market.
